Mestag Therapeutics
Immunology company developing first-in-class antibodies for cancer and inflammatory diseases based on fibroblast biology
Highlights
- New on EvolcAdded 2026-10-30
About Mestag Therapeutics
Mestag Therapeutics is an immunology company developing first-in-class antibody therapies for cancer and inflammatory diseases, built on the role of activated fibroblasts in immune responses. Its MST-0312 programme is a bispecific antibody designed to generate an immune response against cancer cells through the formation of tertiary lymphoid structures in solid tumours, and it is progressing towards a first clinical trial. The M402 programme comprises agonist antibodies targeting a stromal inhibitory receptor, aimed at inflammatory diseases such as RA, IBD and lupus. The company also uses a RAFT target discovery platform to identify new targets.
The pipeline targets patients who do not respond to current cancer therapies or do not achieve durable remission in inflammatory disease. The company's business is the development of its therapeutic pipeline, which it advances in part through strategic pharma partnerships.
Mestag was founded in 2020 by Susan Hill, PhD, who serves as Chief Executive Officer. The company is registered in the United Kingdom, with its headquarters in Saffron Walden, and its laboratory and office facilities are at Chesterford Research Park near Cambridge.
Product: Pipeline of antibody therapeutics for cancer and inflammatory diseases, including MST-0312 and the M402 programme.
Jobs at Mestag Therapeutics
Leadership
- Susan Hill · Chief Executive OfficerSource: company website
More biotech & pharma companies
Metrion Biosciences
Preclinical CRO running ion channel, cardiac safety and neuroscience screening for pharma and biotech drug discoveryNew on EvolcMialgae
Fish-free algae DHA omega-3 ingredient for pet food and aquafeed makers, grown on Scottish whisky by-productsNew on EvolcMicregen
Cell-free stem cell secretome therapies in preclinical development, starting with a treatment for premature-infant NECNew on EvolcMicrobiotica
Clinical-stage biopharma developing microbiome-based live biotherapeutics for melanoma and ulcerative colitis patientsNew on EvolcMicropharm
Develops and manufactures polyclonal antibody medicines, including antivenoms, for healthcare marketsNew on EvolcMidland Pharmaceuticals
Clinical-stage therapeutics for spinal cord injury and ischemic stroke patientsYoung companyNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- BambooHR
- Bootstrap
- Cloudflare
- Cookiebot
- WordPress
- jQuery